Navigation Links
Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum

-Sapirstein to Present Company Overview-

PRINCETON, N.J. and SAN DIEGO, Oct. 23 /PRNewswire/ -- Tobira Therapeutics, Inc., a company focused on the development of medicines with novel mechanisms of actions for infectious diseases, today announced it will present a corporate overview at the 2008 BIO Investor Forum. James Sapirstein, Chief Executive Officer and President will summarize the current status of the company including the status of TBR-652, a CCR5 antagonist in development for HIV-1 infection in adults. The presentation is scheduled for October 30, 2008 at 9:00 AM PST at The Palace Hotel, Two New Montgomery Street, San Francisco, Calif.

"We are delighted to share the growth Tobira Therapeutics, Inc. has experienced in the last 18 months at the BIO Investor Forum," said James Sapirstein. "This is a unique opportunity to review the great potential that we have to offer." Tobira Therapeutics is a clinical stage company and is not developing new technologies. The company is expanding its pipeline by being the partner of choice for suppliers, researchers, and alliance partners. A key component of Tobira's strategy is to acquire global rights to additional product candidates in infectious diseases, while continuing to develop and commercialize new products and line extensions.

The BIO Investor Forum will feature more than 190 public and venture-stage company presentations, in addition to drug and technology therapeutic workshops, breakout sessions, one-on-one investor meetings, and networking with industry executives and investors.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.


Tobira Therapeutics Inc.

Antoinette Bobbitt, Senior Director, Corporate and Business Development Tel: +1 609-897-1102

SOURCE Tobira Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
3. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):